Network analysis of α-synuclein pathology progression reveals p21-activated kinases as regulators of vulnerability

Group II p21-activated kinases (PAKs) are identified as regulators of regional vulnerability to α-synuclein pathology in Parkinson's disease models.

• Why it matters: Understanding why certain brain regions develop more pathology than predicted by connectivity alone can reveal molecular drivers of vulnerability, aiding targeted therapies for Parkinson's disease.
• What they did: The study combined whole brain mapping of α-synuclein pathology in mice with network diffusion modeling and compared regional gene expression profiles, highlighting kinases enriched in vulnerable regions, especially PAKs.
• The result: Pharmacological inhibition and genetic depletion of PAK5/6 reduced α-synuclein aggregation and protected neurons, suggesting PAKs as promising therapeutic targets for modifying disease progression.